Kymera (KYMR) Form 144 Files Proposed 79,220-Share Sale

Rhea-AI Filing Summary

Form 144 filed for Kymera Therapeutics, Inc. (KYMR) reporting a proposed sale of 79,220 shares of common stock through Morgan Stanley Smith Barney LLC on 09/17/2025. The filing shows the shares were acquired the same day by exercise of stock options from the issuer and were paid in cash. The aggregate market value of the shares at the proposed sale is reported as $3,864,351.60 and the company has 71,497,597 shares outstanding per the form. No other securities sales in the past three months are reported and the filer certifies they do not possess undisclosed material adverse information.

Positive

• Transaction fully disclosed: filing specifies acquisition method, payment, broker, proposed sale date and aggregate market value
• Payment in cash: the securities were acquired by exercise of options and paid for in cash on the acquisition date
• No recent sales: the filer reports "Nothing to Report" for securities sold during the past three months

Negative

• None.

Insights

Financial Analyst

TL;DR Insider exercised stock options and intends to sell 79,220 shares worth $3.86M; transaction appears routine and disclosed.

The filing documents a same-day acquisition and proposed sale of common stock by exercise of stock options with cash payment. The position size represents a small portion of the reported outstanding shares (79,220 of 71,497,597). The disclosure aligns with standard Rule 144 reporting requirements and includes broker details (Morgan Stanley Smith Barney LLC) and the proposed sale date. There are no reported sales in the prior three months. From a financial perspective, this is a transparent, routine liquidity event rather than an operational development.

Corporate Governance Expert

TL;DR The Form 144 provides required insider-sale disclosure: option exercise then proposed sale, with certification about material non-public information.

The notice contains the essential governance-related elements: nature of acquisition (exercise of stock options), payment method (cash), broker information, and the filer’s representation about non-public material information. The filing does not identify the selling person's name or relationship in the provided text, and it does not report any contemporaneous sales within the prior three months. This meets the procedural filing standard under Rule 144 but includes limited identifying detail in the excerpt provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	79220	3864351.60	71497597	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2025	Exercise of Stock Options	Issuer			79220	09/17/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Kymera Therapeutics (KYMR) Form 144 report?

The Form 144 reports a proposed sale of 79,220 common shares via Morgan Stanley Smith Barney LLC on 09/17/2025 with an aggregate market value of $3,864,351.60.

How were the KYMR shares acquired according to the filing?

The shares were acquired on 09/17/2025 by exercise of stock options from the issuer and payment was made in cash.

Does the filing show other recent sales by the filer of KYMR stock?

No. The filing lists "Nothing to Report" under securities sold during the past three months.

What broker is handling the proposed KYMR sale?

The proposed sale is being handled by Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What is the reported number of Kymera shares outstanding in the filing?

The Form 144 reports 71,497,597 shares outstanding.